Record Drug Recall Totals for 2009 Resulted from GMP Breakdowns
This article was originally published in The Gold Sheet
Executive Summary
A deluge of drug recalls set a record in 2009. With the past four years now among the top five for recalls, it suggests drug quality could be in a period of decline. Last year's record reflects GMP breakdowns at a drug repacker and several manufacturers that were identified during FDA inspections and led to a variety of sanctions, including warning letters, consent decrees and an import alert. Congress is looking to let FDA mandate recalls, which means the rain of recalls could grow even heavier. Meanwhile, FDA adds suspensions to its enforcement arsenal. International recalls remain rare, though that could change as FDA ramps up enforcement abroad
You may also be interested in...
Contamination and Raw Material Testing Issues Raised in FDA Warning Letters
FDA investigators are continuing to find contamination problems and inadequate testing, according to 20 warning letters issued in the first half of 2013, as well as a troubling trend of repeat observations at Baxter, Hospira and Apotex. Observers say to expect more sterility concerns in future warning letters, particularly involving mold, as FDA ramps up GMP enforcement at compounding pharmacies.
Contamination, Mix-Ups Drive Up Drug Recall Totals for 2012
Injectables eclipsed oral solids as 2012 generated the fourth-most recalls ever. Contamination played a major role, particularly in generating several massive recalls at compounding pharmacies, while there were also contraceptive packaging snafus, problems in confronting tablet mix-ups and other issues that generated drug recalls last year.
Contamination Issues Drove Drug Recalls to Record Levels in 2011
How contamination, sterility assurance, OOS and other issues caused drug recalls to spike again last year. What happened at Aidapak, H&P, Ben Venue, Hospira, Teva and other manufacturers to set a new record.